Phase 1 Deliverable Only: Discovery & Ethnopharmacological Scouting

SCF API DEVELOPMENT PIPELINE FOR INDEVIRATE

Phase 1 Deliverable Only: Discovery & Ethnopharmacological Scouting

Program Context

Indevirate is already defined in the AETERNAVIR development architecture as Payload A with locked SCF role F1 / F3, and its non-negotiable function is viral genome arrest via high-barrier integrase deadlock within an HIV-focused dual-payload program routed through a 505(b)(1) development pathway. The same program document assigns Glymorisulfonin as Payload B and GoldenCSF-AET as the excipient intelligence layer.

A direct ethnobotanical source for Indevirate itself was not explicitly identified in the retrieved files. Accordingly, this Phase 1 deliverable initiates the SCF Ethnobioprospecting Workflow as a reverse-engineering discovery phase for the Indevirate lead lineage, using the existing HIV/integrase program definition as the target product profile and the SCF ethnobioprospecting workflow as the discovery method.

1. Phase 1 Objective

To identify, rank, and justify ethnobioprospecting source systems and candidate natural-product lineages capable of yielding an Indevirate-class antiviral scaffold aligned to the SCF Five Principles:

1. Targeted Drug Action
2. Pharmacokinetic Optimization
3. Metabolic Efficiency
4. Resistance Prevention
5. Safety Profile

This phase follows the defined SCF ethnobioprospecting sequence of:

• collecting ethnobotanical and traditional medicine data,
• screening traditional therapeutic roles,
• mapping usage to modern disease pathways,
• prioritizing candidates for subsequent extraction and mechanistic profiling.

2. Indevirate Target Product Hypothesis for Ethnobioprospecting

Working Mechanistic Target: HIV-1 integrase-centered viral genome arrest with high resistance barrier.

Therapeutic Domain: HIV-1 reservoir suppression/eradication.

Desired SCF Payload Role: F1 Initiator + F3 Amplifier, consistent with the locked AETERNAVIR architecture.

2.1 Required Phase 1 Discovery Traits

The ethnobioprospected source should plausibly support one or more of the following:

• antiviral nucleic-acid or viral-processing interference,
• multi-target immune-viral pressure without diffuse toxicity,
• pharmacokinetic tractability for oral/lymphatic delivery,
• compatibility with resistance-prevention logic,
• fit for later combination with Glymorisulfonin and GoldenCSF-AET.

3. Source-System Selection Logic

The global ethnomedical reference supports scouting across East Asian, South Asian, Amazonian, African, and other traditional systems. For Indevirate, the strongest SCF-aligned discovery logic is to prioritize systems with:

• deep plant-based antiviral or infection-oriented traditions,
• rich alkaloid, polyphenol, terpene, and related molecular classes,
• available SCF-ranked molecular libraries for rapid downstream extraction and scaffold engineering.

3.1 Primary Ethnobioprospecting Corridor Chosen

Amazon Basin ethnomedical and pharmacological corridor

This corridor is selected because the uploaded SCF databases already contain a ranked medicinal-species library, a larger pharmacological super-database, and a compound-to-pathway atlas designed for SCF API discovery progression into extraction, synergy evaluation, and scaffold engineering.

3.2 Supporting Secondary Corridor

Sub-Saharan African molecular pharmacopoeia

This is retained as a secondary comparator corridor because the library contains 1,000+ bioactive molecules with explicit SMILES-ready discovery utility and strong alkaloid representation for scaffold exploration.

4. Phase 1 Candidate Source Pool for Indevirate Lead Discovery

4.1 Tier-1 Amazonian Discovery Candidates

From the Amazon Basin SCF potency-ranked library and super-database, the following are the most relevant candidates for early Indevirate lead-lineage scouting:

The Amazon documents specifically identify Cordycepin as the key Amazon bioactive aligned to antiviral therapy, while Petiveria alliacea, Uncaria tomentosa, and Tabebuia impetiginosa offer supporting roles in resistance prevention, immune modulation, and target-directed small-molecule exploration.

4.2 Tier-2 Molecular Class Priorities

Based on the SCF molecular libraries and the need for an antiviral integrase-deadlock payload, the highest-value discovery classes for Indevirate Phase 1 are:

• Nucleoside-like / cordycepin-like antiviral analog classes
• Alkaloids
• Quinones / naphthoquinone-related families
• Sulfur-rich small molecules for resistance-biasing architecture
• Polyfunctional adjunct classes suitable for oral/lymphatic stack integration

5. Biomedical Translation Map for Indevirate Scouting

This mapping is consistent with the SCF instruction to match traditional use with disease-relevant pathways before extraction and mechanistic profiling.

6. Phase 1 Prioritization Decision

6.1 Lead Ethnobioprospecting Hypothesis

For Indevirate, the strongest Phase 1 starting hypothesis is:

Primary lead lineage: Cordycepin-analog discovery track from Amazon fungal/related antiviral natural-product mapping, supported by adjunct comparator tracks from Petiveria alliacea, Uncaria tomentosa, and Tabebuia impetiginosa.

6.2 Rationale

This ranking is based on four converging factors:

• the AETERNAVIR file locks Indevirate into an antiviral payload role requiring direct genome-arrest logic,
• the SCF opportunity map explicitly tags Cordycepin to antiviral therapy
• the Amazon database is already structured to move directly from Phase 1 into extraction, synergy evaluation, and scaffold engineering,
• the SCF Five Principles require both potency and downstream PK/safety/resistance fit, not single-axis bioactivity alone.

7. Phase 1 Go/No-Go Ranking Matrix

This is a structured SCF screening judgment, not an experimentally validated ranking. Experimental confirmation begins in Phase 2. The logic is based on the SCF principle set, source pharmacology summaries, and the predefined antiviral role of Indevirate.

8. Mandatory Phase 1 Deliverable Outputs

8.1 Ethnopharmacological Scouting Output

Selected Geographic Discovery Region: Amazon Basin

Selected Lead Discovery Axis: Antiviral natural products with scaffold potential for integrase-centered viral genome arrest

Primary Lead Family: Cordycepin-analog antiviral lineage

Comparator Families: Sulfur bioactives, oxindole alkaloids, quinone-class bioactives

8.2 Source Authentication Plan for Phase 2 Transition

Per the extraction protocol, the next phase must include:

• species authentication,
• geographical origin verification,
• phytochemical fingerprinting,
• pathway-alignment screening,
• target tissue/cell selection before extraction.

8.3 Regulatory Framing

Indevirate remains within a small-molecule/new-chemical-entity development logic proceeding through IND and ultimately NDA, consistent with the FDA framework and the AETERNAVIR 505(b)(1) program assignment.

9. Phase 1 Conclusion

Phase 1 is now initiated and completed at the scouting level.

The SCF Ethnobioprospecting Workflow identifies the Amazon Basin as the primary source corridor for Indevirate lead discovery and prioritizes a cordycepin-analog antiviral lineage as the best initial ethnobioprospecting hypothesis for an Indevirate-class Payload A scaffold. Comparator discovery tracks are retained in Petiveria alliacea, Uncaria tomentosa, and Tabebuia impetiginosa to support resistance-barrier design, host-compartment modulation, and scaffold diversification.

Next sequential output: Phase 2 — Bioactive Compound Extraction & SCF Analysis.

Master Registry Index

SCF-HIV-AET-DP-0001 — AETERNAVIR Development Program

SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow

SCF-ABMD-DB-0001 — Amazon Basin Medicinal Species Database

SCF-ABMD-SDB-0002 — Amazon Basin Pharmacological Super-Database

SCF-AMPA-0300 — Amazon Compound Multi-Omic Pathway Atlas

SCF-SEF-MD-0001 — SCF Synergistic Evaluation Framework

SCF-POT-FORM-0001 — SCF Potency Formula Framework

SCF-API-DP-0001 — SCF API Discovery Profile

SCF-REG-HIV-INDEVIRATE-P1-0001 — Indevirate Phase 1 Discovery & Ethnopharmacological Scouting Deliverable